In summary, our findings show that KDELR1 is upregulated in gliomas compared with normal brain tissues and that its expression is significantly associated with clinical features such as the WHO grade, recurrence, molecular classification, IDH mutation, and 1p/19q codeletion status. This evidence concerns the gene KDELR1 and glioma.